Press Releases


Latest News


Adamas Pharmaceuticals to Present at the 2015 JMP Securities Life Science Conference
Jun 9, 2015 | General Releases

Adamas Reports First Quarter 2015 Financial Results
May 13, 2015 | Financial Releases

Adamas Pharmaceuticals Receives Orphan Drug Designation for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease
Apr 10, 2015 | General Releases

Adamas Pharmaceuticals to Present at 2015 Needham Healthcare Conference
Apr 9, 2015 | General Releases

Adamas Pharmaceuticals Issued Patent
Mar 31, 2015 | General Releases

Adamas Reports Fiscal 2014 Financial Results
Mar 3, 2015 | Financial Releases

Adamas Pharmaceuticals' Phase 2/3 Clinical Study Published in Movement Disorders
Feb 9, 2015 | General Releases

Adamas Pharmaceuticals Provides Review of 2014 and Previews Upcoming Business Drivers
Jan 11, 2015 | General Releases

Adamas Pharmaceuticals Receives $30 Million Milestone Payment From Actavis
Jan 8, 2015 | General Releases

Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
Dec 24, 2014 | General Releases

Pages:  1 2 3 4 5 6 7 8 9 10